HEALTH PROFESSIONAL · SOURCE READING

KIT inhibitors

Source: Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 2, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Unresectable Stage III, Stage IV, and Recurrent Melanoma / Treatment Options for Unresectable Stage III, Stage IV, and Recurrent Melanoma / Signal transduction inhibitors

Early data suggest that mucosal or acral melanomas with activating pathogenic variants or amplifications in KIT may be sensitive to a variety of c-KIT inhibitors.[25-27] Phase II and phase III trials are available for patients with unresectable stage III or stage IV melanoma and KIT pathogenic variants.

Source links and citations

Publication references

Read the original reference and check its publication notices.

PubMed 18421059 · Original source
PubMed 21642685 · Original source

Preserved source evidence · Not medical advice